SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia

被引：10
|
作者：
Poulain, Stephanie [1 ]
Ertault, Marjan [2 ]
Leleu, Xavier [3 ]
Coiteux, Valerie [3 ]
Fernandes, Jose [4 ]
Stalnikiewicz, Laure [2 ]
Duthilleul, Patrick [1 ]
Morel, Pierre [2 ]
机构：
[1] Ctr Hosp Valenciennes, Serv Hematol Immunol Cytogenet, Valenciennes, France
[2] Ctr Hosp Schaffner, Serv Hematol Clin, Lens, France
[3] Ctr Hosp Reg Univ, Serv Malad Sang, Lille, France
[4] Ctr Hosp, Serv Hematol Clin, Valenciennes, France
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 09期
关键词：
Waldenstrom macroglobulinemia; SDF1; CXCL12; Polymorphism; CXCR4; CONSENSUS PANEL RECOMMENDATIONS; 2ND INTERNATIONAL WORKSHOP; CHEMOKINE; RECEPTOR; LYMPHOMA; LEUKEMIA; CXCR4; CELLS; RISK; GENE;
D O I：
10.1016/j.leukres.2009.03.031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The interaction of the chemokine CXCL12 with CXCR4 regulates homing of tumoral cells in bone marrow in Waldenstrom, macroglobulinemia (WM). We assessed the distribution and the clinical influence of the CXCL12 (-801GA) polymorphism using PCR RFLP in a series of 114 WM patients. CXCL12 (-801AA) genotype was more frequent in WM patients compared with control subjects (p = 0.01). On the other hand, CXCL12 (-801 GG) patients had a shorter median survival after initiation of first line therapy than remaining patients (p = 0.01). In conclusion, the CXCL12 (-801GA) polymorphism may either be associated with a high incidence of WM or influence clinical outcome. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：1204 / 1207
页数：4
相关论文
共 50 条
  • [1] Clinical influence of SDF1(-801GA), IL6(-174GC) and IL10 (-1082GA) polymorphisms in waldenstrom macroglobulinemia (WM)
    Poulain, S
    Dervite, I
    Leleu, X
    Dumoulard, B
    Fernandes, J
    Stalnikiewicz, L
    Moreau, A
    Coiteux, V
    Duthilleul, P
    Morel, P
    ANNALS OF ONCOLOGY, 2005, 16 : 157 - 157
  • [2] CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of progression
    Pfeffer, U.
    Mirisola, V.
    Zuccarino, A.
    Bachmeier, B.
    Sormani, M. P.
    Falter, J.
    Nerlich, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 141 - 141
  • [3] Prognostic and clinicopathological value of CXCL12/SDF1 expression in breast cancer: A meta-analysis
    Liu, Heyang
    Li, Zhuanzhen
    Deng, Miao
    Liu, Qipeng
    Zhang, Ting
    Guo, Wanying
    Li, Peng
    Qiao, Weiqiang
    CLINICA CHIMICA ACTA, 2018, 484 : 72 - 80
  • [4] The effect of stromal cell-derived factor 1 (SDF1/CXCL12) genetic polymorphism on HIV-1 disease progression
    Reiche, Edna Maria Vissoci
    Watanabe, Maria Angelica Ehara
    Bonametti, Ana Maria
    Morimoto, Helena Kaminami
    Morimoto, Arilson Akira
    Wiechmann, Susana Lilian
    Bregano, Jose Wander
    Matsuo, Tiemi
    Reiche, Fernando Vissoci
    Miranda, Helen Cristina
    Oliveira, Karen Brajao
    Vogler, Ingridt Hildegard
    Siscar, Alexandra Regina
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2006, 18 (04) : 785 - 793
  • [5] Association Between Polymorphism of SDF1 (CXCL12) Gene and HIV-1 Susceptibility: A Meta-Analysis
    Liu, SiJie
    Zhu, HuanZhang
    CURRENT HIV RESEARCH, 2011, 9 (02) : 112 - 119
  • [6] CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival
    Mirisola, Valentina
    Zuccarino, Ambra
    Bachmeier, Beatrice E.
    Sormani, Maria Pia
    Falter, Judith
    Nerlich, Andreas
    Pfeffer, Ulrich
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (14) : 2579 - 2587
  • [7] Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function
    Barbieri, Federica
    Bajetto, Adriana
    Porcile, Carola
    Pattarozzi, Alessandra
    Schettini, Gennaro
    Florio, Tullio
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2007, 38 (3-4) : 383 - 389
  • [8] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia
    Dimopoulos, MA
    Hamilos, G
    Zervas, K
    Symeonidis, A
    Kouvatseas, G
    Roussou, P
    Gika, D
    Karmiris, T
    Bourantas, K
    Zomas, A
    Mitsouli, C
    Xilouri, I
    Vervessou, E
    Matsis, K
    Anagnostopoulos, N
    Economopoulos, T
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1299 - 1305
  • [9] Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF1/CXCL12
    Veldkamp, Christopher T.
    Seibert, Christoph
    Peterson, Francis C.
    De la Cruz, Norberto B.
    Haugner, John C.
    Basnet, Harihar
    Sakmar, Thomas P.
    Volkman, Brian F.
    CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 904 - 904
  • [10] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
    Dimopolous, MA
    Hamilos, G
    Symeonidis, A
    Kouvatseas, G
    Zervas, K
    Panayiotidis, P
    Gika, D
    Karmiris, T
    Bouradas, K
    Grigoraki, V
    Zomas, A
    Anagnostopoulos, N
    Economopoulos, T
    BLOOD, 2002, 100 (11) : 604A - 604A
12345